Does the media refer more to SGMO or EQ?

In the previous week, Equillium had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Equillium and 1 mentions for Sangamo Therapeutics. Equillium's average media sentiment score of 0.60 beat Sangamo Therapeutics' score of 0.40 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RANI or SGMO?

In the previous week, Rani Therapeutics had 4 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 1 mentions for Sangamo Therapeutics. Rani Therapeutics' average media sentiment score of 0.42 beat Sangamo Therapeutics' score of 0.40 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SGMO or OKUR?

In the previous week, OnKure Therapeutics had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 4 mentions for OnKure Therapeutics and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.40 beat OnKure Therapeutics' score of -0.04 indicating that Sangamo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SGMO or TLSA?

Sangamo Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher possible upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, SGMO or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Sangamo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sangamo Therapeutics $39.55M 0.78 -$122.93M -$0.38 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media favor SGMO or TLSA?

In the previous week, Tiziana Life Sciences had 6 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.40 beat Tiziana Life Sciences' score of 0.27 indicating that Sangamo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sangamo Therapeutics (SGMO) Competitors

$0.07 0.00 (0.00%)

As of 09/25/2026

Compare

SGMO vs. EQ, RANI, OKUR, TLSA, and COYA

Should you buy Sangamo Therapeutics stock or one of its competitors? Sangamo Therapeutics's main competitors and comparable companies include Equillium (EQ), Rani Therapeutics (RANI), OnKure Therapeutics (OKUR), Tiziana Life Sciences (TLSA), and Coya Therapeutics (COYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sangamo Therapeutics compare to Equillium?

Sangamo Therapeutics (NASDAQ:SGMO) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Equillium has higher revenue and earnings than Sangamo Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Equillium	$41.10M	2.59	-$22.40M	-$0.20	N/A

Sangamo Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Equillium has a consensus target price of $7.57, indicating a potential upside of 350.68%. Given Sangamo Therapeutics' higher possible upside, equities analysts clearly believe Sangamo Therapeutics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Sangamo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Equillium has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market.

In the previous week, Equillium had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Equillium and 1 mentions for Sangamo Therapeutics. Equillium's average media sentiment score of 0.60 beat Sangamo Therapeutics' score of 0.40 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equillium has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Equillium's return on equity of -41.15% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Equillium	N/A	-41.15%	-38.29%

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Equillium beats Sangamo Therapeutics on 14 of the 17 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Rani Therapeutics had 4 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 1 mentions for Sangamo Therapeutics. Rani Therapeutics' average media sentiment score of 0.42 beat Sangamo Therapeutics' score of 0.40 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rani Therapeutics has higher earnings, but lower revenue than Sangamo Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	66.36	-$29.67M	-$0.27	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Rani Therapeutics has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Rani Therapeutics' return on equity of -104.60% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Rani Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 1,027.58%. Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Rani Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Rani Therapeutics beats Sangamo Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Sangamo Therapeutics compare to OnKure Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, OnKure Therapeutics had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 4 mentions for OnKure Therapeutics and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.40 beat OnKure Therapeutics' score of -0.04 indicating that Sangamo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OnKure Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

Sangamo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

OnKure Therapeutics has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. OnKure Therapeutics' return on equity of -49.01% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
OnKure Therapeutics	N/A	-49.01%	-45.77%

Sangamo Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. OnKure Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 534.06%. Given Sangamo Therapeutics' higher probable upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

OnKure Therapeutics beats Sangamo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Tiziana Life Sciences?

Sangamo Therapeutics (NASDAQ:SGMO) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Tiziana Life Sciences has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Tiziana Life Sciences' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Tiziana Life Sciences	N/A	N/A	N/A

56.9% of Sangamo Therapeutics shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Tiziana Life Sciences has lower revenue, but higher earnings than Sangamo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

In the previous week, Tiziana Life Sciences had 6 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 7 mentions for Tiziana Life Sciences and 1 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.40 beat Tiziana Life Sciences' score of 0.27 indicating that Sangamo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tiziana Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sangamo Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher possible upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Tiziana Life Sciences beats Sangamo Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Coya Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Sangamo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Sangamo Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Coya Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 207.90%. Given Sangamo Therapeutics' higher probable upside, equities research analysts plainly believe Sangamo Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coya Therapeutics has a net margin of -270.22% compared to Sangamo Therapeutics' net margin of -310.81%. Coya Therapeutics' return on equity of -52.05% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Coya Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Coya Therapeutics	$7.95M	14.70	-$21.23M	-$1.07	N/A

In the previous week, Sangamo Therapeutics and Sangamo Therapeutics both had 1 articles in the media. Coya Therapeutics' average media sentiment score of 0.61 beat Sangamo Therapeutics' score of 0.40 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Coya Therapeutics	Positive

Summary

Coya Therapeutics beats Sangamo Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMO vs. The Competition

Export

Metric	Sangamo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.66M	$3.95B	$7.34B	$13.18B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-0.17	8.21	214.73	21.08
Price / Sales	0.78	1,309.60	613.36	83.45
Price / Cash	N/A	40.88	28.02	35.00
Price / Book	-1.85	15.41	10.53	6.44
Net Income	-$122.93M	-$22.71M	$3.50B	$360.47M
7 Day Performance	N/A	-3.19%	-1.73%	-1.03%
1 Month Performance	N/A	-7.64%	-3.76%	-3.70%
1 Year Performance	N/A	28.11%	14.48%	3.62%

Sangamo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMO Sangamo Therapeutics	1.2976 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480	News Coverage
EQ Equillium	2.1509 of 5 stars	$1.90 -1.3%	$7.57 +299.5%	+11.3%	$121.74M	$41.10M	N/A	14	Gap Up
RANI Rani Therapeutics	3.0343 of 5 stars	$0.79 -8.4%	$8.75 +1,008.4%	+58.2%	$120.16M	$1.63M	N/A	69	News Coverage
OKUR OnKure Therapeutics	2.6812 of 5 stars	$3.06 +3.7%	$17.50 +471.9%	+15.5%	$119.17M	N/A	N/A	45
TLSA Tiziana Life Sciences	1.5565 of 5 stars	$0.90 -0.1%	N/A	-51.0%	$115.25M	N/A	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMO) was last updated on 9/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. EQ, RANI, OKUR, TLSA, and COYA

How does Sangamo Therapeutics compare to Equillium?

Summary

How does Sangamo Therapeutics compare to Rani Therapeutics?

Summary

How does Sangamo Therapeutics compare to OnKure Therapeutics?

Summary

How does Sangamo Therapeutics compare to Tiziana Life Sciences?

Summary

How does Sangamo Therapeutics compare to Coya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. EQ, RANI, OKUR, TLSA, and COYA

How does Sangamo Therapeutics compare to Equillium?

Which has preferable valuation and earnings, SGMO or EQ?

Do analysts recommend SGMO or EQ?

Which has more volatility and risk, SGMO or EQ?

Does the media refer more to SGMO or EQ?

Is SGMO or EQ more profitable?

Do institutionals & insiders believe in SGMO or EQ?

Summary

How does Sangamo Therapeutics compare to Rani Therapeutics?

Does the media prefer RANI or SGMO?

Do insiders & institutionals have more ownership in RANI or SGMO?

Which has preferable valuation & earnings, RANI or SGMO?

Is RANI or SGMO more profitable?

Which has more volatility and risk, RANI or SGMO?

Do analysts prefer RANI or SGMO?

Summary

How does Sangamo Therapeutics compare to OnKure Therapeutics?

Does the media refer more to SGMO or OKUR?

Which has preferable valuation and earnings, SGMO or OKUR?

Which has more volatility & risk, SGMO or OKUR?

Is SGMO or OKUR more profitable?

Do analysts recommend SGMO or OKUR?

Do institutionals and insiders hold more shares of SGMO or OKUR?

Summary

How does Sangamo Therapeutics compare to Tiziana Life Sciences?

Is SGMO or TLSA more profitable?

Do institutionals and insiders hold more shares of SGMO or TLSA?

Which has more risk and volatility, SGMO or TLSA?

Which has stronger earnings and valuation, SGMO or TLSA?

Does the media favor SGMO or TLSA?

Do analysts rate SGMO or TLSA?

Summary

How does Sangamo Therapeutics compare to Coya Therapeutics?

Which has more volatility & risk, SGMO or COYA?

Do analysts rate SGMO or COYA?

Is SGMO or COYA more profitable?

Do insiders & institutionals have more ownership in SGMO or COYA?

Which has better earnings & valuation, SGMO or COYA?

Does the media prefer SGMO or COYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools